Together or Apart? Revealing the Impact of Dietary Interventions on Bioavailability of Quinolones: A Systematic Review with Meta-analyses.

IF 4.6 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Clinical Pharmacokinetics Pub Date : 2024-06-01 Epub Date: 2024-05-28 DOI:10.1007/s40262-024-01377-0
Agnieszka Wiesner, Paweł Zagrodzki, Alicja Gawalska, Paweł Paśko
{"title":"Together or Apart? Revealing the Impact of Dietary Interventions on Bioavailability of Quinolones: A Systematic Review with Meta-analyses.","authors":"Agnieszka Wiesner, Paweł Zagrodzki, Alicja Gawalska, Paweł Paśko","doi":"10.1007/s40262-024-01377-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Managing drug-food interactions is essential for optimizing the effectiveness and safety profile of quinolones. Following PRISMA guidelines, we systematically reviewed the influence of dietary interventions on the bioavailability of 22 quinolones.</p><p><strong>Methods: </strong>All studies describing or investigating the impact of food, beverages, antacids, and mineral supplements on pharmacokinetic parameters or pharmacokinetic/pharmacodynamic indices of orally taken quinolones were considered for inclusion. We excluded reviews, in vitro and in silico studies, studies performed on animals, and those involving alcohol. We performed the search in Medline (via PubMed), Embase, and Cochrane Library, covering reports from database inception to December 2022. We used the following tools to assess the risk of bias: version 2 of the Cochrane risk-of-bias tool for parallel trials, the Cochrane risk-of-bias tool for cross-over studies, and the NIH quality assessment tool for before-after studies. We performed quantitative analyses for each quinolone if two or more food-effect studies with specified and comparable study designs were available. If meta-analyses were not applicable, we qualitatively summarized the results.</p><p><strong>Results: </strong>We included 109 studies from 101 reports. Meta-analyses were conducted for 12 antibiotics and qualitative synthesis was employed for the remaining drugs. Of the studies, 60.5% were open-label, cross-over, as recommended by FDA. We judged 46% of studies as having a high risk of bias and only 4% of having a low risk of bias. Among 19 quinolones with available food impact data, 14 (74%) had potentially clinically important interactions. For nalidixic acid, oxolinic acid, and tosufloxacin, food exerted a high positive impact on bioavailability (AUC or C<sub>max</sub> increased by > 45%), whereas, for all the remaining drugs, postprandial absorption was lower. The most significant negative influence of food (AUC or C<sub>max</sub> decreased by > 40%) occurred for delafloxacin capsules and norfloxacin, whereas the moderate influence (AUC or C<sub>max</sub> decreased by 30-40%) occurred for nemonoxacin and rufloxacin. All 14 analysed quinolones showed a substantial reduction in bioavailability when co-administered with antacids and mineral supplements, except for calcium preparations. The impact of beverages was evaluated for 10 quinolones, with 50% experiencing significantly reduced absorption in the presence of milk (the highest negative impact for ciprofloxacin). Moreover, both ciprofloxacin and levofloxacin demonstrated compromised bioavailability when consumed with orange juice, particularly calcium-fortified.</p><p><strong>Discussion: </strong>Several factors may influence interactions, including the physicochemical characteristics of quinolones, the type of intervention, drug formulation, and the patient's health status. We assessed the quality of evidence as low due to the poor actuality of included studies, their methodological diversity, and uneven data availability for individual drugs.</p>","PeriodicalId":10405,"journal":{"name":"Clinical Pharmacokinetics","volume":" ","pages":"773-818"},"PeriodicalIF":4.6000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11222276/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacokinetics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40262-024-01377-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: Managing drug-food interactions is essential for optimizing the effectiveness and safety profile of quinolones. Following PRISMA guidelines, we systematically reviewed the influence of dietary interventions on the bioavailability of 22 quinolones.

Methods: All studies describing or investigating the impact of food, beverages, antacids, and mineral supplements on pharmacokinetic parameters or pharmacokinetic/pharmacodynamic indices of orally taken quinolones were considered for inclusion. We excluded reviews, in vitro and in silico studies, studies performed on animals, and those involving alcohol. We performed the search in Medline (via PubMed), Embase, and Cochrane Library, covering reports from database inception to December 2022. We used the following tools to assess the risk of bias: version 2 of the Cochrane risk-of-bias tool for parallel trials, the Cochrane risk-of-bias tool for cross-over studies, and the NIH quality assessment tool for before-after studies. We performed quantitative analyses for each quinolone if two or more food-effect studies with specified and comparable study designs were available. If meta-analyses were not applicable, we qualitatively summarized the results.

Results: We included 109 studies from 101 reports. Meta-analyses were conducted for 12 antibiotics and qualitative synthesis was employed for the remaining drugs. Of the studies, 60.5% were open-label, cross-over, as recommended by FDA. We judged 46% of studies as having a high risk of bias and only 4% of having a low risk of bias. Among 19 quinolones with available food impact data, 14 (74%) had potentially clinically important interactions. For nalidixic acid, oxolinic acid, and tosufloxacin, food exerted a high positive impact on bioavailability (AUC or Cmax increased by > 45%), whereas, for all the remaining drugs, postprandial absorption was lower. The most significant negative influence of food (AUC or Cmax decreased by > 40%) occurred for delafloxacin capsules and norfloxacin, whereas the moderate influence (AUC or Cmax decreased by 30-40%) occurred for nemonoxacin and rufloxacin. All 14 analysed quinolones showed a substantial reduction in bioavailability when co-administered with antacids and mineral supplements, except for calcium preparations. The impact of beverages was evaluated for 10 quinolones, with 50% experiencing significantly reduced absorption in the presence of milk (the highest negative impact for ciprofloxacin). Moreover, both ciprofloxacin and levofloxacin demonstrated compromised bioavailability when consumed with orange juice, particularly calcium-fortified.

Discussion: Several factors may influence interactions, including the physicochemical characteristics of quinolones, the type of intervention, drug formulation, and the patient's health status. We assessed the quality of evidence as low due to the poor actuality of included studies, their methodological diversity, and uneven data availability for individual drugs.

Abstract Image

一起还是分开?揭示膳食干预对喹诺酮类药物生物利用度的影响:带 Meta 分析的系统综述。
背景和目的:处理药物与食物的相互作用对于优化喹诺酮类药物的有效性和安全性至关重要。根据 PRISMA 指南,我们系统回顾了饮食干预对 22 种喹诺酮类药物生物利用度的影响:所有描述或调查食物、饮料、抗酸剂和矿物质补充剂对口服喹诺酮类药物的药代动力学参数或药代动力学/药效学指标影响的研究均被考虑纳入。我们排除了综述、体外和硅学研究、动物研究以及涉及酒精的研究。我们在 Medline(通过 PubMed)、Embase 和 Cochrane 图书馆进行了检索,涵盖了从数据库建立到 2022 年 12 月的报告。我们使用了以下工具来评估偏倚风险:用于平行试验的 Cochrane 偏倚风险工具第 2 版、用于交叉研究的 Cochrane 偏倚风险工具以及用于前后研究的 NIH 质量评估工具。如果有两项或更多研究设计明确且具有可比性的食物效应研究,我们会对每种喹诺酮类药物进行定量分析。如果荟萃分析不适用,我们则对结果进行定性总结:我们纳入了 101 份报告中的 109 项研究。我们对 12 种抗生素进行了元分析,并对其余药物进行了定性总结。在这些研究中,60.5%是按照美国食品药品管理局的建议进行的开放标签、交叉研究。我们判定 46% 的研究存在高偏倚风险,只有 4% 的研究存在低偏倚风险。在 19 种有食物影响数据的喹诺酮类药物中,14 种(74%)有潜在的重要临床相互作用。对于萘啶酸、氧氟沙星和托舒沙星,食物对其生物利用度有很大的积极影响(AUC 或 Cmax 增加大于 45%),而对于其余所有药物,餐后吸收率较低。食物对德拉氧氟沙星胶囊和诺氟沙星的负面影响最大(AUC 或 Cmax 降低 > 40%),而对奈莫沙星和芦氟沙星的影响适中(AUC 或 Cmax 降低 30-40%)。除钙制剂外,所有 14 种被分析的喹诺酮类药物在与抗酸剂和矿物质补充剂合用时,生物利用度都会大幅降低。对 10 种喹诺酮类药物的饮料影响进行了评估,其中 50%的药物在有牛奶的情况下吸收率明显降低(环丙沙星的负面影响最大)。此外,环丙沙星和左氧氟沙星与橙汁(尤其是钙强化橙汁)一起饮用时,其生物利用度也会受到影响:讨论:影响相互作用的因素有很多,包括喹诺酮类药物的理化特性、干预类型、药物配方以及患者的健康状况。由于纳入研究的实际情况较差、研究方法多样以及个别药物数据的可获得性不均衡,我们将证据质量评定为低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.80
自引率
4.40%
发文量
86
审稿时长
6-12 weeks
期刊介绍: Clinical Pharmacokinetics promotes the continuing development of clinical pharmacokinetics and pharmacodynamics for the improvement of drug therapy, and for furthering postgraduate education in clinical pharmacology and therapeutics. Pharmacokinetics, the study of drug disposition in the body, is an integral part of drug development and rational use. Knowledge and application of pharmacokinetic principles leads to accelerated drug development, cost effective drug use and a reduced frequency of adverse effects and drug interactions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信